Trending stocks

Sanjivani Paranteral revenue dropped on 17.4% in 2015

08-06-2015 • About Sanjivani Paranteral ($SANJIVIN) • By InTwits

Sanjivani Paranteral reported FY2015 financial results today. Overall the company's long term financial model is characterised by the following facts:
  • Sanjivani Paranteral is a company in decline: FY2015 revenue growth was -17.4%, 5 years revenue CAGR was -2.6%
  • EBITDA Margin is declining: in FY2015 vs. 7.5% in FY2014 vs. 7.4% in FY2011
Below you can find a comprehensive analysis of the key data driving the company's performance and stock price.

Sanjivani Paranteral ($SANJIVIN) key annual financial indicators

mln. INR201120122013201420152015/2014
P&L
Revenue1,4411,5051,5231,6111,330-17.4%
EBITDA106133127121-100.0%
Net Income22272616-24-251.4%
Balance Sheet
Cash757
Short Term Debt428445472
Long Term Debt9113768
Cash flow
Capex685
Ratios
Revenue growth-5.2%4.4%1.2%5.8%-17.4%
EBITDA growth-14.1%25.0%-4.4%-5.0%
EBITDA Margin7.4%8.8%8.3%7.5%0.0%-7.5%
Net Income Margin1.5%1.8%1.7%1.0%-1.8%-2.8%
CAPEX, % of revenue0.4%5.7%0.0%
ROIC12.2%14.2%13.0%0.0%
ROE7.8%9.1%7.9%0.0%
Net Debt/EBITDA4.8x4.3x4.2x0.0x0.0x

Revenue and profitability


Sanjivani Paranteral's Revenue dropped on 17.4% in FY2015.

Net Income marign decreased on 2.8 pp from 0.99% to -1.8% in FY2015.


Appendix 1: Peers in Pharmaceuticals


Below we provide Sanjivani Paranteral benchmarking against other companies in Pharmaceuticals industry for the last 5 years. We show data for the top-5 companies by key financial metric together with the median value for all the companies in the industry.

Top companies by Revenue growth, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Mangalam Drugs & Organics ($MANGALAM)16.6%-18.2%-2.1%79.8%
Sun Pharmaceutical Industries ($SUNPHARMA)39.9%40.4%42.4%70.2%
Marksans Pharma ($MARKSANS)16.7%23.3%43.3%26.8%
Torrent Cables ($TORRCABS)27.5%17.4%-42.9%26.5%
Lincoln Pharmaceuticals ($LINCOPH)6.3%3.8%8.5%25.9%
 
Median (39 companies)-37.4%16.7%14.9%13.7%9.2%
Sanjivani Paranteral ($SANJIVIN)1.2%5.8%-17.4%


Top companies by Gross margin, %

Top  FY2011 FY2012 FY2013 FY2014 FY2015
Dr.Reddy'S Laboratories ($DRREDDY)52.1%57.4%57.6%
Omega Laboratories ($OMEGALAB)0.0%0.0%0.0%0.0%
 
Median (2 companies)46.9%26.1%28.7%28.8%


Top companies by EBITDA margin, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Divi'S Laboratories ($DIVISLAB)38.1%37.2%38.2%40.2%37.4%
Hester Biosciences ($HESTERBIO)32.9%
Sun Pharmaceutical Industries ($SUNPHARMA)34.3%40.8%44.3%44.9%29.2%
Natco Pharma ($NATCOPHARM)21.3%21.5%23.2%24.9%26.2%
Dr.Reddy'S Laboratories ($DRREDDY)21.7%25.8%22.9%25.1%23.2%
 
Median (53 companies)16.4%12.9%13.4%15.0%12.1%


Top companies by CAPEX/Revenue, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Claris Lifesciences ($CLARIS)32.5%58.1%42.9%103.1%
Wintac ($WINTAC)22.8%
Hester Biosciences ($HESTERBIO)21.5%
Ipca Laboratories ($IPCALAB)10.3%11.2%8.3%11.6%17.8%
Natco Pharma ($NATCOPHARM)20.0%24.4%16.3%14.4%14.1%
 
Median (31 companies)7.4%8.2%7.9%5.8%6.2%


Top companies by ROIC, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Marksans Pharma ($MARKSANS)-25.8%-142.4%34.9%33.8%41.2%
Alembic Pharmaceuticals ($APLLTD)27.5%29.1%41.5%35.7%
Jenburkt Pharmaceuticals ($JENBURPH)43.6%34.1%29.0%32.4%35.3%
Abbott India ($ABBOTINDIA)36.0%29.6%26.9%30.5%34.2%
Divi'S Laboratories ($DIVISLAB)25.6%30.6%30.4%32.3%30.5%
 
Median (61 companies)13.5%13.7%13.8%15.0%13.3%
Sanjivani Paranteral ($SANJIVIN)14.2%13.0%


Top companies by Net Debt / EBITDA

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Jubilant Life Sciences Limited ($JUBILANT)5.3x4.0x3.5x3.5x6.4x
Shasun Pharmaceuticals ($SHASUNPHAR)4.5x2.8x4.5x6.0x6.2x
Claris Lifesciences ($CLARIS)1.5x1.9x1.1x1.8x3.2x
Dishman Pharmaceuticals & Chemicals ($DISHMAN)3.7x3.6x2.6x2.3x2.9x
Neuland Laboratories ($NEULANDLAB)4.9x4.2x3.5x2.6x2.6x
 
Median (49 companies)1.6x1.4x1.2x0.5x0.1x